Fetal hemoglobin level and nutritional status in patients with sickle cell disease by Sherif M. Badawy
LETTER TO THE EDITOR Open Access
Fetal hemoglobin level and nutritional
status in patients with sickle cell disease
Sherif M. Badawy1,2
Abstract
Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and
there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with
sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients’
nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients
with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea
to patients as young as nine month old of age.
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Correspondance/Findings
Factors determining sickle cell disease severity, and the
relationship between fetal hemoglobin level and patients
nutritional status.
To the editor
With great interest, I have read an article by Mandese et
al [1], recently published in Nutrition Journal. The study
reported on the nutritional status among children with
sickle cell disease (SCD) in relation to disease severity
and other morbidity outcomes. The authors reported a
negative correlation between fetal hemoglobin levels and
the intake of carbohydrates, lipids, iron, phosphorus,
vitamins B1, and B2, suggesting a beneficial effect that
low intake of these nutritional elements [1]. However, I
would like to highlight two points. First, the authors
used a number of measures to examine disease severity,
however the evidence to support the rationale for choosing
the measures was unclear. Second, Mandese et al presented
some data in Table 2 in their article that do not match the
text [1]. All reported correlations (r2) related to intake of
different nutritional elements have positive significant
values suggesting direct relationship, including mean fetal
hemoglobin level, the number of hospitalizations and the
number of days for hospitalizations in the year prior. I won-
der if the authors could explain this further. Hydroxyurea is
the only medication approved by the U.S. Food and Drug
Administration for SCD, and there is strong evidence to
support the efficacy and the cost effectiveness of using
hydroxyurea is patients with SCD by increasing fetal
hemoglobin levels [2–4]. Therefore, it is important to clarify
the relationship between patients’ nutritional status/intake
and fetal hemoglobin levels. In particular, hydroxyurea has
been recommended for patients with poor growth [3], and
the recent guidelines from the National Institute of Health
suggested offering hydroxyurea to patients as young as nine
month old of age [5].
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In relation to the first point we think that the number
of hospitalizations for vaso-occlusive crisis (VOC), days
of hospitalization per year and number of Acute Chest
Syndrome (ACS) during life are the best modality to
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identify patients with worst outcomes. On the other
hand, VOC and ACS represent the most frequent com-
plications in sickle cell disease [6–8].
The number of severe episodes of VOC (requiring
hospitalization) and of ACS drives the clinicians in the
decision to start the therapy with hydroxyurea (HU) or
continue the close follow-up of these patients [9]. We
reported an inverse correlation between number and day
of hospitalizations per year and fetal hemoglobin levels
with intake of carbohydrates, lipids, iron, phosphorus,
vitamins B1, and B2, but with these data we don’t want
to suggest a beneficial effect of low intake of these nutri-
tional elements for these patients. We would like to
highlight that these data were unexpected even for us
and further studies with more patients are needed to
clarify the relationship between nutritional intake and
fetal hemoglobin irrespectively from HU therapy. We
are aware that HU is the only medication approved by
the U.S. Food and Drug Administration and EMA for
SCD and that there is a strong evidence to support the
efficacy and the cost effectiveness of using HU in pa-
tients with SCD even from the first years of life [10–12].
Accordingly, many patients in follow-up in our center
are treated with HU for its beneficial effects on SCD.
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